CSL Behring Will Discontinue Carimune NF in Third Quarter 2018

CSL Behring is discontinuing the production of Carimune NF (immune globulin [human] nanofiltered) in the third quarter of 2018. Discontinuation of the product is due to the preference among healthcare professionals and patients for newer, more advanced immune globulin options. In a letter to providers of the product, the company wrote: “Consideration of yield is especially important when dealing with a resource as precious as human plasma. Discontinuation of Carimune NF will allow CSL Behring to dedicate more resources to Privigen and Hizentra, which yield higher rates of immunoglobulin. Over the long term, CSL Behring will be able to supply more immunoglobulin to the market due to greater yield and manufacturing efficiencies.”

Providers who have questions are asked to contact their local CSL Behring representative.